Jaguar Health Inc. (NASDAQ: JAGX) announced it has regained compliance with NASDAQ's publicly held shares requirement and received an extension until May 18, 2026, to meet the exchange's minimum bid price rule.

The company received a decision letter on May 6, 2026, from the NASDAQ Hearings Panel granting the extension request. NASDAQ had previously notified Jaguar on May 1, 2026, that it failed to meet the minimum 500,000 publicly held shares requirement under Listing Rule 5550(a)(4).

Following the exercise of existing pre-funded warrants by third-party investors on May 4, 2026, Jaguar regained compliance with the publicly held shares requirement. The warrant exercises resulted in the purchase of common stock that brought the company back into compliance.

The company remains subject to NASDAQ's minimum $1.00 bid price requirement under Listing Rule 5550(a)(2). To demonstrate compliance with this rule, Jaguar must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days.

The NASDAQ panel stated that the company's previous non-compliance with the publicly held shares requirement reset the timeline for achieving bid price compliance. The panel granted an additional one-day extension from the original May 15, 2026 deadline to May 18, 2026.

Under NASDAQ rules, the company would remain non-compliant with both requirements until the publicly held shares requirement was cured and the minimum bid price maintained for the required consecutive business days.